Visible Genetics faces increased loss
This article was originally published in Clinica
Executive Summary
Visible Genetics has revised its accounting treatment for international and licensing transactions following conversations with its auditors. This has resulted in an increased loss for the first quarter as the company is forced to recognise previously announced income over subsequent periods.